Kinase inhibitors for treatment of disease
Disclosed are therapeutic compositions including BA-1076 and/or BA-2057, methods of their use in the treatment of ophthalmological disorders. The therapeutic compositions may further include an IOP-lowering prostaglandin. The methods may further include administration of an IOP-lowering prostaglandin.
1. A therapeutic composition comprising a therapeutically effective amount of a compound of formula:
or a pharmaceutically acceptable salt thereof,
wherein BA-1076 or a pharmaceutically acceptable salt thereof is present in at least 10% enantiomeric excess.
2. The therapeutic composition of claim 1 , further comprising a therapeutically effective amount of a compound of formula:
or a pharmaceutically acceptable salt thereof,
wherein BA-2057 or a pharmaceutically acceptable salt thereof is present in at least 10% enantiomeric excess.
3. A therapeutic composition comprising a therapeutically effective amount of a compound of formula:
or a pharmaceutically acceptable salt thereof,
wherein BA-2057 or a pharmaceutically acceptable salt thereof is present in at least 10% enantiomeric excess.
4. The therapeutic composition of claim 3 , wherein BA-2057 is present in at least 50% enantiomeric excess.
5. The therapeutic composition of claim 1 , wherein BA-1076 is present in at least 50% enantiomeric excess.
6. The therapeutic composition of claim 1 , further comprising latanoprost, travaprost, bimatoprost, or tafluprost.
7. The therapeutic composition of claim 1 , wherein the therapeutic composition is formulated for ocular topical administration, intravitreal administration, intraocular administration, retinal administration, oral administration, or intravenous administration.
8. The therapeutic composition of claim 7 , wherein the therapeutic composition is in a dosage form of eye drops, formulated for oral administration, or formulated for intravenous administration.
9. The therapeutic composition of claim 1 , wherein the therapeutic composition comprises the compound at a concentration of 0.001% to 5% (w/v) or at a dose of 0.01 mg/kg to 10 mg/kg.
10. A method of treating glaucoma, retinitis pigmentosa, macular degeneration, or retinal angiogenesis in a subject in need thereof, comprising administering to the subject a therapeutically-effective amount of the therapeutic composition of claim 1 .
11. The method of claim 10 , wherein the method is for treating glaucoma in the subject.
12. The method of claim 10 , wherein the therapeutic composition is administered topically, intravitreally, intraocularly, retinally to the eye, orally, or intravenously.
13. The method of claim 10 , wherein the method further comprises administering travaprost, bimatoprost, latanoprost, or tafluprost.
14. The method of claim 10 , wherein the method of treating corneal scarring comprises reducing post-operative corneal scarring in a subject in need thereof.
15. The therapeutic composition of claim 3 , further comprising latanoprost, travaprost, bimatoprost, or tafluprost.
16. A method of treating glaucoma, retinitis pigmentosa, macular degeneration, or retinal angiogenesis in a subject in need thereof, comprising administering to the subject a therapeutically-effective amount of the therapeutic composition of claim 3 .
17. The method of claim 16 , wherein the method is for treating glaucoma in the subject.
18. The method of claim 16 , wherein the therapeutic composition is administered topically, intravitreally, intraocularly, retinally to the eye, orally, or intravenously.
19. The method of claim 16 , wherein the method further comprises administering travaprost, bimatoprost, latanoprost, or tafluprost.